ASCO 2021: New progress in skin cancer immunotherapy (continuous update)

1.

About CheckMate 067 research:

The study compared nivolumab and ipilimumab alone and in combination in the treatment of patients with stage III or IV melanoma who were previously untreated and unresectable.

In the trial, patients were randomly assigned to receive nivolumab combined with ipilimumab, nivolumab, or ipilimumab alone.

The median survival time also follows the same pattern.

The study authors believe: "This 6.

The clinical trial was supported by Bristol-Myers Squibb.

2.

About the RELATIVITY-047 study:

So far, phase III studies evaluating immune checkpoint inhibitor combinations have only demonstrated clinical benefit by blocking the PD-1 and CTLA-4 pathways.

The RELATIVITY-047 study is the first randomized phase III trial evaluating the fixed-dose combination of immunotherapy drugs nivolumab and relatlimab, and is applicable to patients with previously untreated, unresectable or metastatic melanoma.

A total of 714 patients were enrolled in the study, and they were randomly assigned to receive a fixed-dose combination therapy of nivolumab and relatlimab or to receive nivolumab alone in a 1:1 ratio.

The researchers found that compared with nivolumab alone, the median progression-free survival of nivolumab combined with relatlimab was significantly longer: 10.

Adverse events associated with nivolumab combined with relatlimab therapy are usually controllable, reflecting the typical safety of immune checkpoint inhibitors.

Researchers are waiting for objective responses and overall survival results.

Immunotherapy has changed the treatment prospects for patients with advanced melanoma.